From Wikipedia, the free encyclopedia
|Source||Humanized (from mouse)|
|Mol. mass||145.3 kDa|
|(what is this?)|
This drug was developed by Immunomedics, Inc.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab, American Medical Association.
- Rossi, E. A.; Goldenberg, D. M.; Cardillo, T. M.; Stein, R.; Chang, C. -H. (2009). "CD20-targeted tetrameric interferon- , a novel and potent immunocytokine for the therapy of B-cell lymphomas". Blood 114 (18): 3864. doi:10.1182/blood-2009-06-228890. PMC 2773491. PMID 19710501.
- ClinicalTrials.gov NCT00546793 Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|